The ongoing TATTON trail evaluating the efficacy of Osimertinib combined with Savolitinib, a potent c-Met inhibitor, in NSCLC patients who progressed on Osimertinib with c-Met-mediated machinery got encouraging results and represented a promising therapy to overcome resistance to Osimertinib [12]. Here, MET is linked to non-small cell lung carcinoma.